KalVista Pharmaceuticals (NASDAQ:KALV) Stock Rating Lowered by Citizens Jmp

KalVista Pharmaceuticals (NASDAQ:KALV) was downgraded by Citizens Jmp from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

A number of other research firms have also recently issued reports on KALV. Stifel Nicolaus raised their target price on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 21st. HC Wainwright raised their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Needham & Company LLC reiterated a “hold” rating on shares of KalVista Pharmaceuticals in a research note on Thursday. Finally, Wall Street Zen cut KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 21st. Four investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $32.60.

KalVista Pharmaceuticals Stock Performance

Shares of KALV opened at $26.66 on Wednesday. The business’s fifty day moving average price is $18.45 and its 200 day moving average price is $15.72. KalVista Pharmaceuticals has a 12-month low of $9.83 and a 12-month high of $26.76. The stock has a market capitalization of $1.37 billion, a PE ratio of -6.75 and a beta of -0.40. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21.

Insider Transactions at KalVista Pharmaceuticals

In other news, insider Nicole Sweeny sold 1,862 shares of the company’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $20.22, for a total value of $37,649.64. Following the completion of the sale, the insider owned 51,391 shares in the company, valued at $1,039,126.02. This represents a 3.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Benjamin L. Palleiko sold 9,550 shares of the business’s stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $20.22, for a total transaction of $193,101.00. Following the completion of the sale, the chief executive officer owned 462,577 shares in the company, valued at approximately $9,353,306.94. This trade represents a 2.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 263,969 shares of company stock valued at $4,536,178 over the last three months. 4.30% of the stock is owned by company insiders.

Institutional Trading of KalVista Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets boosted its holdings in KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 1,292 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of KalVista Pharmaceuticals in the third quarter valued at $55,000. Wolverine Asset Management LLC bought a new position in shares of KalVista Pharmaceuticals in the third quarter valued at $57,000. KLP Kapitalforvaltning AS bought a new position in shares of KalVista Pharmaceuticals in the third quarter valued at $63,000. Finally, Truvestments Capital LLC increased its holdings in shares of KalVista Pharmaceuticals by 253.8% in the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after buying an additional 3,360 shares in the last quarter.

Key Stories Impacting KalVista Pharmaceuticals

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Chiesi Group agreed to acquire KalVista for about $1.9 billion and to buy shares for $27.00 in cash — the deal highlights Chiesi’s push into rare-disease/HAE treatment Ekterly and is the primary catalyst for the stock’s jump. Chiesi to buy KalVista in $1.9B deal
• Positive Sentiment: Market reaction: shares surged roughly 38–39% on the takeover news and trading volume spiked well above average, reflecting investor demand to capture the cash takeover consideration. KalVista stock surges 39%
• Neutral Sentiment: Trading mechanics: trading in KALV was temporarily halted prior to the announcement for “news pending,” a routine step that precedes major corporate news and can amplify post-release moves. (Company/regulatory filings reflected the halt.)
• Neutral Sentiment: Analyst view: Needham & Company reaffirmed a “hold” rating on KalVista — a reminder some analysts view the takeover price as fair or limited upside beyond the offer. Needham reaffirms hold
• Negative Sentiment: Litigation risk: multiple shareholder-alerts and law-firm investigations (Ademi LLP and Monteverde & Associates) have been announced questioning whether the $27.00 per-share deal is fair and whether fiduciary duties were met — these actions could delay closing, prompt a negotiated price change, or produce settlement costs. Ademi LLP shareholder alert Monteverde investigation

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.